Development And Manufacturing Services Agreement Sample Contracts

Atara Biotherapeutics – Development and Manufacturing Services Agreement (August 1st, 2018)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of August 10, 2015 (the "Effective Date") by and between ATARA BIOTHERAPEUTICS, INC, a Delaware corporation with an office at 701 Gateway Blvd, Suite 200, South San Francisco, CA 94080 ("Atara") and COGNATE BIOSERVICES, INC., a Delaware corporation, with an office at 7513 Connelly Drive, Suite I, Hanover, MD 21076 ("Manufacturer").

Denali Therapeutics Inc. – Amendment No. 2 to the DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT Dated 6th September 2017 Between LONZA SALES AG and DENALI THERAPEUTICS lNC. (March 19th, 2018)

NOW THEREFORE in consideration of the mutual promises and covenants contained herein and other good and valuable consideration the sufficiency of which is acknowledged, it is hereby agreed by and between the Parties to amend the Agreement as follows:

Development and Manufacturing Services Agreement (August 7th, 2017)

This agreement is made as of April 14, 2017 ("Effective Date") between CMC ICOS BIOLOGICS, INC., a Washington corporation ("CMC"), and AGENUS INC., a Delaware corporation ("Customer").

Cytodyn Inc – Development and Manufacturing Services Agreement (April 13th, 2017)

This agreement is made as of November 9, 2016 (Effective Date) between CMC ICOS BIOLOGICS, INC., a Washington corporation (CMC), and CYTODYN INC., a Delaware corporation (Customer).

Asterias Biotherapeutics, Inc. – Development and Manufacturing Services Agreement (November 14th, 2016)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of August 3, 2016 (the "Effective Date") by and between ASTERIAS BIOTHERAPEUTICS, INC., a Delaware corporation with an office at 6300 Dumbarton Circle, Fremont, CA 94555 ("Asterias") and COGNATE BIOSERVICES, INC., a Delaware corporation, with an office at 7513 Connelly Drive, Suite I, Hanover, MD 21076 ("Cognate").

Targacept – Development and Manufacturing Services Agreement (August 4th, 2016)

This Development and Manufacturing Services Agreement (this "Agreement") is made as of May 20, 2016 ("Effective Date") between CMC ICOS BIOLOGICS, INC., a Washington corporation ("CMC"), and Catalyst Biosciences, Inc., a Delaware Corporation ("Customer").

Radius Health, Inc. – Amendment No. 4 to Development and Manufacturing Services Agreement (May 5th, 2016)

This Amendment No. 4 (the Amendment) to the DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is entered into on March 31, 2016 by and between Radius Health Inc., a Delaware corporation, with its principal office at 950 Winter Street, Waltham, MA 02451, United States of America (RADIUS) and LONZA Sales Ltd, a Swiss company having an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (together with its Affiliates, Manufacturer) and upon execution will be incorporated into the Development and Manufacturing Services Agreement between RADIUS and Manufacturer dated October 16, 2007 (the Original Agreement), as amended to date. Capitalized terms used in this Amendment will have the same meaning as set forth in the Agreement as amended to date.

Radius Health, Inc. – Amendment No. 3 to Development and Manufacturing Services Agreement (February 25th, 2016)

This Amendment No. 3 (the Amendment) to the DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is entered into on December 31, 2015 by and between Radius Health Inc., a Delaware corporation, with its principal office at 950 Winter Street, Waltham, MA 02451, United States of America (RADIUS) and LONZA Sales Ltd, a Swiss company having an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (together with its Affiliates, Manufacturer) and upon execution will be incorporated into the Development and Manufacturing Services Agreement between RADIUS and Manufacturer dated October 16, 2007 (the Original Agreement), as amended to date. Capitalized terms used in this Amendment will have the same meaning as set forth in the Agreement as amended to date.

Amended and Restated Development and Manufacturing Services Agreement (November 9th, 2015)

THIS AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into effective as of July 6, 2015 (the Effective Date) by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation having an address at 300 Third Street, Third Floor, Cambridge, Massachusetts 02142 (together with its Affiliates, Alnylam) and Agilent Technologies, Inc., a Delaware corporation having an address at 5555 Airport Blvd, Suite 100, Boulder CO 80301 (Manufacturer).

Telik, Inc. – Confidential Treatment Requested Development and Manufacturing Services Agreement (August 12th, 2015)

This DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, effective as of this 15th day of April 2014 (the "Effective Date"), between, MabVax Therapeutics, a Delaware Corporation ("Customer"), having its principal place of business at 11588 Sorrento Valley Road, Suite 20, San Diego CA 92121, and Gallus Biopharmaceuticals NJ, LLC, a Delaware limited liability company with offices at 201 College Road East, Princeton, NJ 08540 ("Gallus"). Customer and Gallus are referred to herein each as a "Party" and collectively as the "Parties".

Anterios Inc – A Request for Confidential Treatment Has Been Made With Respect to Portions of the Following Document That Are Marked With [*]. The Redacted Portions Have Been Filed Separately With the SEC. First Amendment to Development and Manufacturing Services Agreement (April 30th, 2015)

This first amendment to the DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (hereinafter referred to as the First Amendment) is entered into between the QuaDPharma, LLC, a Delaware Limited Liability Company (QuaDPharma); and Anterios, Inc., a Delaware corporation, with offices located at 60 East 42nd St, New York, New York 10165 (Anterios); and is made as of April 23, 2015.

Anterios Inc – A Request for Confidential Treatment Has Been Made With Respect to Portions of the Following Document That Are Marked With [*]. The Redacted Portions Have Been Filed Separately With the SEC. DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (April 27th, 2015)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of August 17, 2011 (the Effective Date) by and between Anterios, Inc., a Delaware corporation having an address at 142 West 57th (Suite 4A), New York, NY 10019, (Anterios) and QuaDPharma, a New York corporation having an address at 11342 Main St., Clarence, New York, 14031 (Manufacturer).

Galmed Pharmaceuticals Ltd. – Development and Manufacturing Services Agreement (March 31st, 2015)

This Development and Manufacturing Services Agreement (the "Agreement") is made and entered into as of January 26, 2015 (the "Effective Date") by and between Perrigo API Ltd., an Israeli company, having its principal offices at 29 Lehi Street, Bnei Brak 51200, Israel ("Perrigo"), Galmed Research and Development Ltd. an Israeli company having its principal offices at 8, Shaul Ha'Melech Blvd., Tel Aviv 6473307, Israel ("Galmed"). The parties identified above are sometimes hereinafter individually referred to as a "Party" and collectively as the "Parties".

Anterios Inc – Development and Manufacturing Services Agreement (March 31st, 2015)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of August 17, 2011 (the Effective Date) by and between Anterios, Inc., a Delaware corporation having an address at 142 West 57th (Suite 4A), New York, NY 10019, (Anterios) and QuaDPharma, a New York corporation having an address at 11342 Main St., Clarence, New York, 14031 (Manufacturer).

Aduro BioTech – Process Development and Manufacturing Services Agreement (March 11th, 2015)

For and in consideration of the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the Parties, the Parties hereto agree to perform and to be bound by their respective obligations and shall have the respective rights set forth in this Agreement.

Radius Health, Inc. – Development and Manufacturing Services Agreement (March 10th, 2015)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of October 16, 2007 (the Effective Date) by and between RADIUS HEALTH, INC., a Delaware corporation having an address at 300 Technology Square, 5th Floor, Cambridge, MA 02139 (together with its Affiliates, RADIUS) and LONZA Sales Ltd, a Swiss company having an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (together with its Affiliates, Manufacturer).

Aduro BioTech – Process Development and Manufacturing Services Agreement (March 2nd, 2015)

For and in consideration of the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the Parties, the Parties hereto agree to perform and to be bound by their respective obligations and shall have the respective rights set forth in this Agreement.

Anterios Inc – Development and Manufacturing Services Agreement (February 12th, 2015)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of August 17, 2011 (the Effective Date) by and between Anterios, Inc., a Delaware corporation having an address at 142 West 57th (Suite 4A), New York, NY 10019, (Anterios) and QuaDPharma, a New York corporation having an address at 11342 Main St., Clarence, New York, 14031 (Manufacturer).

Telik, Inc. – Confidential Treatment Requested Development and Manufacturing Services Agreement (October 14th, 2014)

This DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, effective as of this 15th day of April 2014 (the Effective Date), between, MabVax Therapeutics, a Delaware Corporation (Customer), having its principal place of business at 11588 Sorrento Valley Road, Suite 20, San Diego CA 92121, and Gallus Biopharmaceuticals NJ, LLC, a Delaware limited liability company with offices at 201 College Road East, Princeton, NJ 08540 (Gallus). Customer and Gallus are referred to herein each as a Party and collectively as the Parties.

Process Development and Manufacturing Services Agreement (September 16th, 2014)

This Process Development and Manufacturing Services Agreement (this Agreement) is effective as of September 1, 2009 (the Effective Date), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (PROTEON), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (LONZA) (each, a Party and together the Parties).

Kolltan Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Askterisks Denote Omissions. DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT Between LONZA SALES AG and KOLLTAN PHARMACEUTICALS, INC. (September 12th, 2014)
Rhythm Holding Company, LLC – Development and Manufacturing Services Agreement (August 27th, 2014)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of July 2, 2010 (the Effective Date) by and between RHYTHM PHARMACEUTICALS, INC., a Delaware corporation with offices at The John Hancock Tower, 54th Floor, 200 Clarendon Street, Boston, MA 02116, USA (Rhythm) and PEPTISYNTHA Inc., a US company incorporated under the laws of the state of Delaware with its registered office at 20910 Higgins Court, Torrance, California 90501 (United States of America) (collectively Manufacturer).

Rhythm Holding Company, LLC – Development and Manufacturing Services Agreement (August 27th, 2014)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of July 17, 2013 (the Effective Date) by and between RHYTHM METABOLIC, INC., a Delaware corporation with offices at 855 Boylston Street, 11th Floor, Boston, MA 02116, USA (Rhythm) and PEPTISYNTHA Inc., a US company incorporated under the laws of the state of Delaware with its registered office at 3333 Richmond Avenue, Houston Texas 77098, USA (Manufacturer).

Process Development and Manufacturing Services Agreement (August 26th, 2014)

This Process Development and Manufacturing Services Agreement (this Agreement) is effective as of September 1, 2009 (the Effective Date), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (PROTEON), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (LONZA) (each, a Party and together the Parties).

Development and Manufacturing Services Agreement (August 13th, 2014)

This DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, effective as of this __ day of ___________, 2014 (the "Effective Date"), between, Omni Bio Pharmaceutical, Inc., a Colorado corporation ("Customer"), having its principal place of business at 5350 S. Roslyn Street, Suite 430 Greenwood Village, CO 80111 and Gallus Biopharmaceuticals, LLC, a Delaware limited liability company with offices at 4766 LaGuardia Drive, St. Louis, MO 63134 ("Gallus"). Customer and Gallus are referred to herein each as a "Party" and collectively as the "Parties".

Kolltan Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Askterisks Denote Omissions. DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT Between LONZA SALES AG and KOLLTAN PHARMACEUTICALS, INC. (August 8th, 2014)
Rhythm Holding Company, LLC – Development and Manufacturing Services Agreement (July 15th, 2014)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of July 2, 2010 (the Effective Date) by and between RHYTHM PHARMACEUTICALS, INC., a Delaware corporation with offices at The John Hancock Tower, 54th Floor, 200 Clarendon Street, Boston, MA 02116, USA (Rhythm) and PEPTISYNTHA Inc., a US company incorporated under the laws of the state of Delaware with its registered office at 20910 Higgins Court, Torrance, California 90501 (United States of America) (collectively Manufacturer).

Rhythm Holding Company, LLC – Development and Manufacturing Services Agreement (July 15th, 2014)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of July 17, 2013 (the Effective Date) by and between RHYTHM METABOLIC, INC., a Delaware corporation with offices at 855 Boylston Street, 11th Floor, Boston, MA 02116, USA (Rhythm) and PEPTISYNTHA Inc., a US company incorporated under the laws of the state of Delaware with its registered office at 3333 Richmond Avenue, Houston Texas 77098, USA (Manufacturer).

Process Development and Manufacturing Services Agreement (June 25th, 2014)

This Process Development and Manufacturing Services Agreement (this Agreement) is effective as of September 1, 2009 (the Effective Date), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (PROTEON), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (LONZA) (each, a Party and together the Parties).

Radius Health, Inc. – Amendment No. 2 to Development and Manufacturing Services Agreement (February 11th, 2014)

This Amendment No. 2 (the Amendment) to the DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is entered into on January 30, 2014 by and between Radius Health Inc., a Delaware corporation, with its principal office at 201 Broadway 6th floor, Cambridge, MA 02139, United States of America (RADIUS), and LONZA Sales Ltd, a Swiss company having an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (together with its Affiliates, Manufacturer), and upon execution will be incorporated into the Development and Manufacturing Services Agreement between RADIUS and Manufacturer dated October 16, 2007 (the Original Agreement), as amended to date. Capitalized terms in this Amendment will have the same meanings as set forth in the Agreement, as amended to date.

Xencor – Development and Manufacturing Services Agreement (November 4th, 2013)

This Development and Manufacturing Services Agreement (Agreement) is made as of this 15th day of September, 2005 (Effective Date), by and between Xencor, Inc., a Delaware corporation, with a place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (hereinafter Xencor) and Cardinal Health PTS, LLC, a Delaware limited liability company, by and through its Gala Biotech business unit with a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 (hereinafter Cardinal Health).

Xencor – Development and Manufacturing Services Agreement (October 25th, 2013)

This Development and Manufacturing Services Agreement (Agreement) is made as of this 15th day of September, 2005 (Effective Date), by and between Xencor, Inc., a Delaware corporation, with a place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (hereinafter Xencor) and Cardinal Health PTS, LLC, a Delaware limited liability company, by and through its Gala Biotech business unit with a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 (hereinafter Cardinal Health).

Xencor – Development and Manufacturing Services Agreement (October 11th, 2013)

This Development and Manufacturing Services Agreement (Agreement) is made as of this 15th day of September, 2005 (Effective Date), by and between Xencor, Inc., a Delaware corporation, with a place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (hereinafter Xencor) and Cardinal Health PTS, LLC, a Delaware limited liability company, by and through its Gala Biotech business unit with a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 (hereinafter Cardinal Health).

Development and Manufacturing Services Agreement (April 12th, 2013)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of January 17, 2007 (the Effective Date) by and between Portola Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, California 94080 (Telephone: 650-246-7300, Facsimile: 650-246-7776) (Portola) and Hovione Inter Limited, a Swiss company having its principal place of business at Bahnhofstrasse 21 CH-6000 Lucerne 7 Switzerland, (Hovione, together with its Affiliates Manufacturer).

Development and Manufacturing Services Agreement (March 13th, 2013)

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of January 17, 2007 (the Effective Date) by and between Portola Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, California 94080 (Telephone: 650-246-7300, Facsimile: 650-246-7776) (Portola) and Hovione Inter Limited, a Swiss company having its principal place of business at Bahnhofstrasse 21 CH-6000 Lucerne 7 Switzerland, (Hovione, together with its Affiliates Manufacturer).